Statin use and the risk of prostate cancer: A metaanalysis of 6 randomized clinical trials and 13 observational studies

被引:122
作者
Bonovas, Stefanos [1 ,2 ]
Filioussi, Kalitsa [1 ]
Sitaras, Nikolaus M. [1 ]
机构
[1] Univ Athens, Sch Med, Dept Pharmacol, GR-11527 Athens, Greece
[2] Ctr Dis Control & Prevent, Dept Epidemiol Surveillance & Intervent, Athens, Greece
关键词
statins; prostate cancer; chemoprevention; epidemiology; metaanalysis;
D O I
10.1002/ijc.23550
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Statins have been suggested to prevent prostate cancer. Our aim was to examine statin use in relation to both total prostate cancer and the more clinically important advanced prostate cancer, through a detailed metaanalysis of the epidemiologic studies published on the subject in peer-reviewed literature. A comprehensive search for articles published up to November 2007 was performed, reviews of each study were conducted and data were abstracted. Prior to metaanalysis, the studies were evaluated for publication bias and heterogeneity. Pooled relative risk (RR) estimates and 95% confidence intervals (CIs) were calculated using the random-effects model. Subgroup and sensitivity analyses were also performed. Nineteen studies [6 randomized clinical trials (RCTs), 6 cohort and 7 case-control studies] contributed to the analysis. There was no evidence of an association between statin use and total prostate cancer among either RCTs (RR = 1.06, 95% CI: 0.93-1.20) or the observational studies (RR = 0.89, 95% CI: 0.65-1.24). However, high heterogeneity was detected among the observational studies. Moreover, long-term statin use did not significantly affect the risk of total prostate cancer (RR = 0.93, 95% CI: 0.77-1.13). In contrast, synthesis of the available reports that had specifically examined statin use in relation to advanced prostate cancer indicated a protective association (RR = 0.77, 95% CI: 0.64-0.93). Our results do not support the hypothesis that statins reduce the risk of total prostate cancer. However, further research is required to investigate whether the particular association of statin use with lower risk of advanced prostate cancer is indeed causal. (c) 2008 Wiley-Liss, Inc.
引用
收藏
页码:899 / 904
页数:6
相关论文
共 59 条
[51]  
Simes RJ, 2002, LANCET, V359, P1379
[52]  
Singal R, 2005, J CLIN ONCOL, V23, p107S
[53]   Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells [J].
Sivaprasad, Umasundari ;
Abbas, Tarek ;
Dutta, Anindya .
MOLECULAR CANCER THERAPEUTICS, 2006, 5 (09) :2310-2316
[54]   Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S) [J].
Strandberg, TE ;
Pyörälä, K ;
Cook, TJ ;
Wilhelmsen, L ;
Faergeman, O ;
Thorgeirsson, G ;
Pedersen, TR ;
Kjekshus, J .
LANCET, 2004, 364 (9436) :771-777
[55]   Meta-analysis of observational studies in epidemiology - A proposal for reporting [J].
Stroup, DF ;
Berlin, JA ;
Morton, SC ;
Olkin, I ;
Williamson, GD ;
Rennie, D ;
Moher, D ;
Becker, BJ ;
Sipe, TA ;
Thacker, SB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (15) :2008-2012
[56]   Socioeconomic gradient in use of statins among Danish patients: population-based cross-sectional study [J].
Thomsen, RW ;
Johnsen, SP ;
Olesen, AV ;
Mortensen, JT ;
Boggild, H ;
Olsen, J ;
Sorensen, HT .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 60 (05) :534-542
[57]   Are GP practice prescribing rates for coronary heart disease drugs equitable? A cross sectional analysis in four primary care trusts in England [J].
Ward, PR ;
Noyce, PR ;
St Leger, AS .
JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 2004, 58 (02) :89-96
[58]   Hypertriglyceridemia as a possible risk factor for prostate cancer [J].
Wuermli, L ;
Joerger, M ;
Henz, S ;
Schmid, HP ;
Riesen, WF ;
Thomas, G ;
Krek, W ;
Cerny, T ;
Gillessen, S .
PROSTATE CANCER AND PROSTATIC DISEASES, 2005, 8 (04) :316-320
[59]  
Zhuang LY, 2002, CANCER RES, V62, P2227